BLOCKADE OF THE CYTOKINE STORM IN SEVERE SARS-COV-2 INFECTION: DRUG SUPPRESSION OR EXTRACORPOREAL ELIMINATION?
-
Published:2020
Issue:5
Volume:18
Page:505-512
-
ISSN:2221-8785
-
Container-title:Journal of the Grodno State Medical University
-
language:
-
Short-container-title:Journal GrSMU
Abstract
Background: The urgency of the treatment of severe COVID-19 is due to high mortality rate both in general patient population (6.4%) and in patients in intensive care units (25.8%). The cytokine storm is a pathological condition leading to high mortality. There are 2 approaches to reducing inflammatory cytokines in blood: blocking their production by drugs and extracorporeal removal. However, the choice is rather challenging.Purpose: A literature analysis was carried out to study modern approaches to prescribing medications and using extracorporeal detoxification for the blockade of the cytokine storm in severe COVID-19 patients.Material and methods: A total of 47 literature sources were analyzed.Results: The obtained information on modern methods of blocking the cytokine storm in severe COVID-19 infection indicates the effectiveness of both tocilizumab and selective anticytokine hemosorption as well as plasmapheresis and methods of renal replacement therapy.Conclusion: Based on our clinical observations, it was found out that not only drug suppression of inflammatory cytokines but also methods of extracorporeal blood purification can be effective in the treatment of severe COVID-19 pneumonia.
Publisher
Grodno State Medical University
Reference47 articles.
1. 1. World Health Organization. Coronavirus disease 2019 (COVID-19). Situation Report 127. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200526-covid-19-sitrep-127.pdf?sfvrsn$=$7b6655ab_8. 2. 2. Auld S, Caridi-Scheible M, Blum JM, Robichaux CJ, Kraft CS, Jacob JT, Jabaley CS, Carpenter D, Kaplow R, Hernandez AC, Adelman MW, Martin SG, Coopersmith CM, Murphy DJ. ICU and ventilator mortality among critically ill adults with COVID-19. medRxiv [Preprint]. 2020 [posted 2020 April 26]. Available from: https://doi.org/10.1101/2020.04.23.20076737. 3. 3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S014067362030183-5. 4. 4. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-848. https://doi.org/10.1007/s00134-020-05991-x. 5. 5. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J. Clin. Invest. 2020;130(5):2620-2629. doi: 10.1101/2020.02.16.20023903.
|
|